From lab to life: The Oral Semaglutide Innovation Story

Background:

​

Developed by Novo Nordisk, oral semaglutide is the first oral GLP-1 receptor agonist (RA) for the treatment of type 2 diabetes. The journey to make semaglutide available in a pill has taken 15 years. This is the story of how Novo Nordisk achieved this.

Creative concept:

The oral semaglutide 'lab to life' journey is a long and complicated one. It was therefore important to develop a visual language that unpacked the journey simply. To achieve this we used clean, modern infographics in an animated video that guided the viewer through the story simply, so that it was easy to understand.

The content was shared with the media and placed onto Novo Nordisk's platforms. 

​